{"id":"ipi-549","safety":{"commonSideEffects":[{"rate":"30%","effect":"Fatigue"},{"rate":"20%","effect":"Diarrhea"},{"rate":"15%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"IPI-549 is a potent and selective inhibitor of PI3K/mTOR, which plays a critical role in cell growth and survival. By inhibiting this pathway, IPI-549 has shown promise in treating various cancers.","oneSentence":"PI3K/mTOR inhibitor","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:02:38.764Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Solid tumors"},{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT07439211","phase":"PHASE1","title":"Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Jacqueline Garcia, MD","startDate":"2026-07","conditions":"Leukemia, Myeloid, Leukemia, Acute Myeloid Leukemia","enrollment":48},{"nctId":"NCT03795610","phase":"PHASE2","title":"IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Assuntina G. Sacco, MD","startDate":"2020-03-06","conditions":"Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer, Head and Neck Carcinoma","enrollment":16},{"nctId":"NCT03719326","phase":"PHASE1","title":"A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies","status":"COMPLETED","sponsor":"Arcus Biosciences, Inc.","startDate":"2018-10-15","conditions":"TNBC - Triple-Negative Breast Cancer, Ovarian Cancer","enrollment":35},{"nctId":"NCT03961698","phase":"PHASE2","title":"Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma","status":"UNKNOWN","sponsor":"Infinity Pharmaceuticals, Inc.","startDate":"2019-12-17","conditions":"Breast Cancer, Renal Cell Carcinoma","enrollment":91},{"nctId":"NCT03980041","phase":"PHASE2","title":"Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)","status":"COMPLETED","sponsor":"Infinity Pharmaceuticals, Inc.","startDate":"2019-09-25","conditions":"Bladder Cancer, Urothelial Carcinoma, Solid Tumor","enrollment":49},{"nctId":"NCT02637531","phase":"PHASE1","title":"A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549","status":"UNKNOWN","sponsor":"Infinity Pharmaceuticals, Inc.","startDate":"2015-12","conditions":"Advanced Solid Tumors (Part A/B/C/D), Non-small Cell Lung Cancer (Part E), Melanoma (Part E)","enrollment":219}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Eganelisib"],"phase":"phase_2","status":"active","brandName":"IPI-549","genericName":"IPI-549","companyName":"Arcus Biosciences, Inc.","companyId":"arcus-biosciences-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PI3K/mTOR inhibitor Used for Solid tumors, Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}